SM-130686

SM-130686 is a chemical compound that is classified as a non-peptide vasopressin V1b receptor antagonist. It was developed by Shionogi, a Japanese pharmaceutical company, and has been studied for its potential therapeutic applications in various neurological disorders and endocrine disorders.

Chemistry

SM-130686 is a non-peptide compound, which means it does not contain amino acid sequences typically found in peptides. This characteristic gives it certain advantages over peptide-based drugs, such as improved stability and potential for oral administration.

Mechanism of Action

SM-130686 works by blocking the vasopressin V1b receptor. Vasopressin, also known as antidiuretic hormone (ADH), is a neurotransmitter that plays a key role in maintaining water balance in the body. The V1b receptor is one of three types of vasopressin receptors and is primarily found in the pituitary gland and certain areas of the brain. By blocking this receptor, SM-130686 can potentially modulate the effects of vasopressin.

Potential Therapeutic Applications

Research has suggested that SM-130686 may have potential therapeutic applications in the treatment of various neurological and endocrine disorders. These include depression, anxiety disorders, post-traumatic stress disorder (PTSD), and Cushing's syndrome.

In preclinical studies, SM-130686 has shown promise in reducing depressive-like behaviors in animal models. It has also been suggested that the compound could be useful in treating anxiety disorders and PTSD, as these conditions have been linked to abnormalities in the vasopressin system.

In the context of endocrine disorders, SM-130686 has been studied for its potential use in treating Cushing's syndrome. This condition is characterized by an overproduction of cortisol, a hormone that is regulated by the vasopressin V1b receptor. By blocking this receptor, SM-130686 could potentially help to normalize cortisol levels.

Development Status

As of now, SM-130686 is still in the experimental stage and has not been approved for clinical use. Further research is needed to fully understand its safety, efficacy, and potential therapeutic applications.

See Also

• Vasopressin
• Vasopressin receptor
• Shionogi
• Non-peptide